中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.016 seconds)

    Antibodies to human IL-1β
    11.
    发明授权
    Antibodies to human IL-1β 有权
    人IL-1和bgr的抗体

    公开(公告)号：US08273350B2

    公开(公告)日：2012-09-25

    申请号：US13171631

    申请日：2011-06-29

    Applicant: Hermann Gram ,  Franco E Di Padova

    Inventor： Hermann Gram ,  Franco E Di Padova

    IPC: A61K39/395 ,  A61K39/00 ,  C07K16/24 ,  C07K16/00 ,  C12P21/08

    CPC classification number: C07K16/245 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34

    Abstract: An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

    Abstract translation: IL-1和bgr 特别是对人IL-1和bgr的抗体，特别是人IL-1和bgr的人抗体; 其中重链和轻链的CDR具有如所定义的氨基酸序列，用于治疗IL-1介导的疾病或病症，例如， 骨关节炎，骨质疏松症和其他炎症性关节炎。

    Methods of Treating Kawasaki Disease using IL-1beta Antibodies
    15.
    发明申请
    Methods of Treating Kawasaki Disease using IL-1beta Antibodies 有权
    使用IL-1beta抗体治疗川崎病的方法

    公开(公告)号：US20160002328A1

    公开(公告)日：2016-01-07

    申请号：US14861191

    申请日：2015-09-22

    Applicant: Hermann Gram ,  Thomas Jung

    Inventor： Hermann Gram ,  Thomas Jung

    IPC: C07K16/24

    CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

    Abstract translation: 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物（本文中称为“IL-1β化合物”）的新用途。 例如破坏IL-1b配体-IL-1受体相互作用的小分子化合物，IL-1b抗体或IL-1受体抗体。 本文所述的IL-1b结合分子，例如 本文公开的抗体，例如 IL-1b结合化合物或IL-1受体结合化合物，和/或降低IL-1b配体或IL-1受体蛋白水平的RNA化合物，用于治疗和/或预防自身炎症综合征。 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

    Methods of Using IL-1beta Compounds
    16.
    发明申请
    Methods of Using IL-1beta Compounds 有权
    使用IL-1β化合物的方法

    公开(公告)号：US20150322148A1

    公开(公告)日：2015-11-12

    申请号：US14810556

    申请日：2015-07-28

    Applicant: Philip Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    Inventor： Philip Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    IPC: C07K16/24

    CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

    Abstract translation: 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物（本文中称为“IL-1β化合物”）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如， 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，哺乳动物，特别是人类。

    Novel Use of IL-1beta Compounds
    18.
    发明申请
    Novel Use of IL-1beta Compounds 有权
    IL-1β化合物的新用途

    公开(公告)号：US20120039910A1

    公开(公告)日：2012-02-16

    申请号：US13283165

    申请日：2011-10-27

    Applicant: Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    Inventor： Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

    IPC: A61K39/395 ,  A61P37/02

    CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

    Abstract translation: 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物（本文中称为“IL-1β化合物”）的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如， 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

    Antibodies to human IL-1β
    20.
    发明授权
    Antibodies to human IL-1β 有权
    人IL-1和bgr的抗体

    公开(公告)号：US07993878B2

    公开(公告)日：2011-08-09

    申请号：US12238502

    申请日：2008-09-26

    Applicant: Hermann Gram ,  Franco E Di Padova

    Inventor： Hermann Gram ,  Franco E Di Padova

    IPC: C12N15/00 ,  C12N5/00 ,  C12N5/07 ,  C12N1/00 ,  C07H21/04 ,  C07K16/00

    CPC classification number: C07K16/245 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34

    Abstract: An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

    Abstract translation: IL-1和bgr 特别是对人IL-1和bgr的抗体，特别是人IL-1和bgr的人抗体; 其中重链和轻链的CDR具有如所定义的氨基酸序列，用于治疗IL-1介导的疾病或病症，例如， 骨关节炎，骨质疏松症和其他炎症性关节炎。

Patent Agency Ranking